Related Experiment Videos
Progressive Multifocal Leukoencephalopathy.
1Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, Lexington, KY 40536-0284, USA. jrbneuro@pop.uky.edu
Current Treatment Options in Neurology
|November 30, 2000
Summary
Establishing a definitive diagnosis of progressive multifocal leukoencephalopathy (PML) is crucial. Improving immune status and discontinuing immunosuppression are key management strategies, with antiretroviral therapy beneficial for AIDS patients.
Area of Science:
- Neuroimmunology
- Viral Pathogenesis
- Clinical Neurology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease.
- PML is caused by the JC virus (JCV) in immunocompromised individuals.
- Current treatment options for PML are limited and often ineffective.
Purpose of the Study:
- To review the current understanding of PML diagnosis and management.
- To evaluate the efficacy of various therapeutic strategies for PML.
- To identify prognostic factors for survival in PML patients.
Main Methods:
- Review of existing literature on PML diagnosis, treatment, and outcomes.
- Analysis of clinical data and case reports.
- Discussion of in vitro and in vivo studies of anti-JCV agents.
Main Results:
- No therapy has proven effective in prospective trials; supportive care and immune reconstitution are primary.
- Antiretroviral therapy (ART) prolongs survival in HIV-associated PML.
- Cytosine arabinoside and other in vitro active agents have shown limited clinical success due to poor brain penetration or toxicity.
Conclusions:
- Diagnosis must be unequivocal before experimental therapies.
- Immune reconstitution is the cornerstone of PML management.
- Further research and well-designed trials are needed to develop effective curative strategies for PML.